Related references
Note: Only part of the references are listed.An Exacerbate-reverse Strategy in Yeast Identifies Histone Deacetylase Inhibition as a Correction for Cholesterol and Sphingolipid Transport Defects in Human Niemann-Pick Type C Disease
Andrew B. Munkacsi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
Ying Sun et al.
PLOS ONE (2011)
Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function
Chunzhang Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts
Nina H. Pipalia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
Jiro Kikuchi et al.
BLOOD (2010)
The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of β-glucosidase
Richie Khanna et al.
FEBS JOURNAL (2010)
Molecular Basis of Reduced Glucosylceramidase Activity in the Most Common Gaucher Disease Mutant, N370S
Marc N. Offman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma Laboratory investigation
Jie Lu et al.
JOURNAL OF NEUROSURGERY (2010)
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis
Darren M. Hutt et al.
NATURE CHEMICAL BIOLOGY (2010)
Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl
Jie Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Evan T. Powers et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2009)
Histone Deacetylase Inhibitors: Potential in Cancer Therapy
P. A. Marks et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Chemical and biological approaches synergize to ameliorate protein-folding diseases
Ting-Wei Mu et al.
CELL (2008)
Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2007)
Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease
Raquel L. Lieberman et al.
NATURE CHEMICAL BIOLOGY (2007)
An acetylation site in the middle domain of Hsp90 regulates chaperone function
Bradley T. Scroggins et al.
MOLECULAR CELL (2007)
Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention
Zhanqian Yu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug
Paul A. Marks et al.
NATURE BIOTECHNOLOGY (2007)
The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanisms
Richard A. Steet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes
Umut Oezcan et al.
SCIENCE (2006)
Therapeutic strategies to ameliorate lysosomal storage disorders - a focus on Gaucher disease
A. R. Sawkar et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2006)
Chemical chaperones and permissive temperatures alter the cellular locatization of Gaucher disease associated glucocerebrosidase variants
Anu R. Sawkar et al.
ACS CHEMICAL BIOLOGY (2006)
Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain
KO Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Impaired trafficking of mutants of lysosomal glucocerebrosidase in Gaucher's disease
M Schmitz et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Heat shock response modulators as therapeutic tools for diseases of protein conformation
SD Westerheide et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity
I Ron et al.
HUMAN MOLECULAR GENETICS (2005)
Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways
AJ McClellan et al.
CELL (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
Twin pairs showing discordance of phenotype in adult Gaucher's disease
RH Lachmann et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2004)
Celastrols as inducers of the heat shock response and cytoprotection
SD Westerheide et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Gaucher disease: Variability in phenotype among siblings
D Amato et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2004)
Share Paper
